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BACKGROUND
Vitamin D deficiency is a common, potentially reversible contributor to morbidity 
and mortality among critically ill patients. The potential benefits of vitamin D 
supplementation in acute critical illness require further study.
METHODS
We conducted a randomized, double-blind, placebo-controlled, phase 3 trial of 
early vitamin D3 supplementation in critically ill, vitamin D–deficient patients who 
were at high risk for death. Randomization occurred within 12 hours after the 
decision to admit the patient to an intensive care unit. Eligible patients received a 
single enteral dose of 540,000 IU of vitamin D3 or matched placebo. The primary 
end point was 90-day all-cause, all-location mortality.
RESULTS
A total of 1360 patients were found to be vitamin D–deficient during point-of-care 
screening and underwent randomization. Of these patients, 1078 had baseline vita-
min D deficiency (25-hydroxyvitamin D level, <20 ng per milliliter [50 nmol per 
liter]) confirmed by subsequent testing and were included in the primary analysis 
population. The mean day 3 level of 25-hydroxyvitamin D was 46.9±23.2 ng per 
milliliter (117±58 nmol per liter) in the vitamin D group and 11.4±5.6 ng per milli-
liter (28±14 nmol per liter) in the placebo group (difference, 35.5 ng per milliliter; 
95% confidence interval [CI], 31.5 to 39.6). The 90-day mortality was 23.5% in the 
vitamin D group (125 of 531 patients) and 20.6% in the placebo group (109 of 528 
patients) (difference, 2.9 percentage points; 95% CI, −2.1 to 7.9; P = 0.26). There 
were no clinically important differences between the groups with respect to sec-
ondary clinical, physiological, or safety end points. The severity of vitamin D de-
ficiency at baseline did not affect the association between the treatment assign-
ment and mortality.
CONCLUSIONS
Early administration of high-dose enteral vitamin D3 did not provide an advantage 
over placebo with respect to 90-day mortality or other, nonfatal outcomes among 
critically ill, vitamin D–deficient patients. (Funded by the National Heart, Lung, 
and Blood Institute; VIOLET ClinicalTrials.gov number, NCT03096314.)
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Vitamin D may improve outcomes in critically ill patients. Preclinical data sug-gest that vitamin D is a potent immuno-
modulatory agent that is essential for lung devel-
opment and function.1-7 Observational data and 
initial clinical trial data indicate that vitamin D 
deficiency is common among critically ill patients 
and constitutes a potentially modifiable risk fac-
tor associated with longer lengths of stay in the 
hospital and intensive care unit (ICU), lung and 
other organ injury, prolonged mechanical venti-
lation, and death.8-14 However, vitamin D level is 
considered a marker of coexisting conditions 
and frailty, and residual confounding may drive 
these associations.15
In a previous phase 2 trial (Correction of 
Vitamin D Deficiency in Critically Ill Patients 
[VITdAL-ICU], involving 475 patients), vitamin D 
supplementation administered to vitamin D–defi-
cient, critically ill patients was associated with 
lower observed mortality than placebo at 28 days 
(21.9% vs. 28.6%, P = 0.14) and at 6 months 
(35.0% vs. 42.9%, P = 0.09), although the trial 
was underpowered for analysis of the mortality 
end point.16 Such findings, along with meta-
analyses of previous trials in critical illness sug-
gesting benefit of vitamin D treatment,17,18 sup-
port the need for a larger, phase 3 trial to evaluate 
the effect of short-term vitamin D supplementa-
tion on mortality among critically ill patients.
Accordingly, the National Heart, Lung, and 
Blood Institute (NHLBI) Prevention and Early 
Treatment of Acute Lung Injury (PETAL) Net-
work conducted the Vitamin D to Improve Out-
comes by Leveraging Early Treatment (VIOLET) 
trial. We hypothesized that early administration 
of high-dose vitamin D3 (cholecalciferol) would 
reduce 90-day all-cause, all-location mortality 
among critically ill, vitamin D–deficient patients 
who were at high risk for death.
Me thods
Trial Design and Oversight
We designed the present multicenter, double-
blind, placebo-controlled, phase 3 trial to have 
many similarities to the previous phase 2 trial,16 
including the vitamin D3 regimen (a single enteral 
dose of 540,000 international units [IU]), the 
threshold for vitamin D deficiency (25-hydroxy-
vitamin D level, <20 ng per milliliter [50 nmol 
per liter]), and a focus on critically ill patients. 
Key differences in the present trial included early 
intervention (often before ICU admission), a focus 
on patients with specific higher-risk conditions, 
and a primary analysis based on measurement 
of 25-hydroxyvitamin D by the criterion standard 
of liquid chromatography–tandem mass spec-
trometry.19
The members of the writing committee vouch 
for the accuracy and completeness of the data 
and for the fidelity of the trial to the protocol 
and statistical analysis plan, which are available 
with the full text of this article at NEJM.org. 
Oversight was provided by a central institutional 
review board and data and safety monitoring 
board of the sponsoring network, which were 
appointed by the NHLBI. The trial was conducted 
under an investigational new drug application 
with the Food and Drug Administration (FDA). 
The study network coordinating center managed 
and analyzed the data. We obtained written in-
formed consent from patients (when possible) 
or from their authorized representatives. Sekisui 
Diagnostics supplied the FastPack IP systems 
and Bio-Tech Pharmacal developed and produced 
the high-dose vitamin D3 and placebo used in the 
trial, but neither company had any role in the trial 
design or conduct, data analysis, or data inter-
pretation.
Patients
We enrolled each patient within 12 hours after 
the clinician’s decision to admit the patient to 
the ICU from the emergency department, hospi-
tal ward, operating room, or outside facility. Eli-
gible patients were adults and had one or more 
acute risk factors for death or lung injury that 
contributed directly to the need for ICU admis-
sion (pneumonia, sepsis, shock, mechanical ven-
tilation for acute respiratory failure, aspiration, 
smoke inhalation, pancreatitis, or lung contu-
sion). The complete list of exclusion criteria is 
shown in Figure 1, and in the Supplementary 
Appendix, available at NEJM.org; the most com-
Figure 1 (facing page). Screening, Enrollment,  
and Follow-up.
Patients may have had more than one reason for being 
excluded after the assessment of eligibility, and patients 
who underwent randomization may have had more than 
one reason for not receiving the assigned intervention. 
ICU denotes intensive care unit, and LC‑MS‑MS liquid 
chromatography–tandem mass spectrometry.
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2624 Provided consent
15,924 Patients were assessed for eligibility
13,300 Were excluded
3942 Were unable to undergo randomization
within 12 hr after ICU admission
1967 Declined to participate or were 
withdrawn by surrogate
1514 Were unable to take medication 
by mouth or enteral tube
1422 Did not have surrogate who could
be located
828 Had >72 hr since hospital presentation
822 Decided to withhold or withdraw life-
sustaining treatment
670 Had mechanical ventilation exclusions
599 Had known kidney stone in the past yr
or history of multiple (>1) previous 
kidney stone episodes
571 Had baseline serum calcium >10.2 mg/dl
(2.55 mmol/liter) or ionized
calcium >5.2 mg/dl (1.30 mmol/liter)
524 Were expected to have <48-hr survival
1241 Had other reasons
1264 Screened negative for vitamin D
deficiency
1360 Screened positive for vitamin D
deficiency
1360 Underwent randomization
17 Did not receive placebo
3 Were given vitamin D
in error
2 Withdrew consent
4 Could not take anything
by mouth
3 Did not have nasogastric
tube available
1 Was unavailable
6 Were not in stable
condition
2 Underwent randomization
but were not included in the
analysis
1 Received placebo but had not
provided adequate consent
1 Withdrew consent
14 Did not receive vitamin D
1 Was given placebo in error
1 Withdrew consent
2 Did not have trial drug
tube available
4 Could not take anything
by mouth
3 Did not have nasogastric
tube available
1 Was unavailable
3 Were not in stable
condition
690 Were assigned to vitamin D 668 Were assigned to placebo
7 Were lost to follow-up 12 Were lost to follow-up
531 Were included in the analysis of the
primary end point
528 Were included in the analysis of the
primary end point
538 Were confirmed by LC-MS-MS to have
vitamin D deficiency and were included
 in the primary analysis population
540 Were confirmed by LC-MS-MS to have
vitamin D deficiency and were included
 in the primary analysis population
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mon reasons for patients being excluded were an 
inability to take an enteral drug, a history of 
kidney stones, the presence of hypercalcemia at 
baseline, and informed consent not being ob-
tained in a timely manner. After written in-
formed consent was obtained, eligible patients 
underwent an FDA-approved test to screen for 
vitamin D deficiency — either a test conducted 
by the enrolling hospital clinical laboratory or a 
point-of-care test (FastPack IP, Sekisui Diagnos-
tics) performed by research staff. Eligible pa-
tients had a plasma 25-hydroxyvitamin D level of 
less than 20 ng per milliliter as measured by 
either test. This “screened-deficient” population, 
which included all patients who underwent ran-
domization, subsequently underwent confirma-
tory liquid chromatography–tandem mass spec-
trometry testing, which was completed at the 
University of Washington reference laboratory 
on batched plasma specimens that were collect-
ed at the same time as the initial screening test 
(before randomization). Patients with a 25-hydroxy-
vitamin D level of less than 20 ng per milliliter 
as measured by liquid chromatography–tandem 
mass spectrometry were considered to have con-
firmed vitamin D deficiency and made up the 
primary analysis population. We also obtained 
results for the screened-deficient population as 
secondary analyses. Figure S1 in the Supple-
mentary Appendix shows the flow of patients 
through the trial.
Randomization
We used a central electronic system and permuted 
blocks to randomly assign eligible patients in a 
1:1 ratio, stratified according to site, to receive 
either a single enteral (administered orally or 
through a nasogastric or orogastric tube) dose of 
540,000 IU of vitamin D3 or matched placebo, in 
liquid form, administered within 2 hours after 
randomization. We did not mandate other as-
pects of clinical care, because our intention was 
to evaluate the intervention in the context of 
usual practice. We recommended that treating 
clinicians avoid vitamin D testing or additional 
vitamin D supplementation in the 1 month after 
administration of vitamin D or placebo.
End Points
The primary end point was 90-day all-cause, all-
location mortality in the primary analysis popu-
lation (i.e., patients with vitamin D deficiency 
confirmed by liquid chromatography–tandem 
mass spectrometry). Secondary clinical end points 
were hospital length of stay to day 90, health 
care facility length of stay to day 90, proportions 
of patients alive and at home (previous level of 
care) at day 90, ventilator-free days to day 28, 
time to death to day 90, and quality of life to day 
90. Secondary physiological end points were the 
severity of hypoxemia, acute respiratory distress 
syndrome, acute kidney injury, and cardiovascular 
failure to day 7, as well as 25-hydroxyvitamin D 
levels at day 3 (measured in a subgroup of the 
first 25% of patients per protocol). Safety end 
points were total and ionized calcium levels to 
day 14, incident kidney stones to day 90, and 
fall-related fractures to day 90.
Statistical Analysis
We based the sample size on a comparison of 
binomial proportions with an overall two-sided 
alpha level of 0.05. Under assumptions that 90-
day mortality would be 20% in the placebo group 
and 15% in the vitamin D group, that three in-
terim data analyses would be conducted, and that 
vitamin D deficiency would be confirmed by 
liquid chromatography–tandem mass spectrom-
etry in 80% of the patients undergoing random-
ization, we calculated that the trial would have 
87% power if 3000 patients underwent random-
ization. The design allowed stopping for efficacy 
on the basis of the Lan–DeMets alpha spending 
function.20 The futility stopping rules incorpo-
rated the observed mortality and the proportion 
of patients who underwent randomization who 
had 25-hydroxyvitamin D levels of less than 20 ng 
per milliliter as measured by liquid chromatog-
raphy–tandem mass spectrometry to calculate 
the predictive probability of vitamin D supple-
mentation being shown to be significantly supe-
rior to placebo with 3000 patients. We adopted 
a futility boundary of 10% posterior probability 
of superiority at interim analyses.
For the primary analysis, we compared 90-
day mortality on the risk-difference scale using 
a generalized linear model with a binomial dis-
tribution and identity link function. We used 
quadratic smoothing splines with prespecified 
knots at plasma 25-hydroxyvitamin D levels 
(measured by liquid chromatography–tandem 
mass spectrometry) of 5, 10, 15, 20, 25, and 30 ng 
per milliliter and pointwise 95% bootstrap con-
fidence intervals to estimate the relationship 
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between the treatment effect and the baseline 
25-hydroxyvitamin D level.21 We compared time 
to death to day 90 using Kaplan–Meier curves. 
We compared adverse events with the event as 
the unit of analysis using weighted Poisson re-
gression with serious events given a weight twice 
that of the nonserious events.
We present other secondary end points with 
observed differences and 95% Wald confidence 
intervals. For the comparison of the highest cre-
atinine levels and highest cardiovascular Sequen-
tial Organ Failure Assessment (SOFA) scores to 
day 7, controlling for baseline values, we used 
repeated-measures analysis of variance with a 
treatment-by-time interaction and shared inter-
cept at baseline. We analyzed hospital and health 
care facility length of stay among patients who 
survived to day 90 and changes in quality of life 
as measured with the European Quality of Life–5 
Dimensions 5-Level questionnaire (EQ-5D-5L)22 
(score at day 90 minus score at baseline) using 
survivor average causal effect methods, including 
a model for predicting survival.23 In each treat-
ment group, the estimated outcome in those 
who would survive in both treatment groups is 
a weighted average of the observed outcomes, 
with weights proportional to the estimated prob-
ability of survival in the other treatment group. 
The prespecified covariates were age, sex, race 
or ethnic group, Charlson comorbidity index, 
SOFA score, and baseline 25-hydroxyvitamin D 
level measured by liquid chromatography–tandem 
mass spectrometry. Beyond the survivor average 
causal effect models, we conducted all analyses 
using a complete case analysis approach, assum-
ing that data were missing completely at random.
The main analyses used intention-to-treat 
principles. We considered a two-sided P value of 
less than 0.05 to indicate statistical significance 
for the primary analysis. Other reported P values 
(shown only for safety end points) and confi-
dence intervals were not adjusted for multiple 
comparisons and should not be used to infer 
effects. We used SAS software, version 9.4 (SAS 
Institute), for the analyses.
R esult s
Patients
From April 2017 through July 2018 at 44 U.S. 
hospitals, we obtained consent from 2624 pa-
tients; 1360 patients who were screened as vita-
min D–deficient underwent randomization, and 
1078 of these patients had vitamin D deficiency 
confirmed by liquid chromatography–tandem 
mass spectrometry and were included in the pri-
mary analysis population (Fig. 1). After the first 
interim analysis, the data and safety monitoring 
board recommended that the trial be stopped for 
futility, primarily on the basis of a predictive 
probability of less than 2% that vitamin D treat-
ment would be found to be superior to placebo 
with full trial enrollment.
Overall, 690 patients were assigned to the 
vitamin D group and 668 patients were assigned 
to the placebo group. In the primary analysis 
population, 538 patients were in the vitamin D 
group and 540 were in the placebo group. Base-
line characteristics were similar in the two treat-
ment groups in both the screened-deficient 
population and the primary analysis population 
(Table 1 and Table S1). The most common quali-
fying conditions were pneumonia, shock, and 
sepsis. Randomization was performed at a mean 
(±SD) of 6.7±3.5 hours after the clinician’s deci-
sion to admit the patient to the ICU (Table S2).
Plasma Vitamin D Levels
In the primary analysis population of 1078 pa-
tients, 532 (98.9%) of those who were randomly 
assigned to the vitamin D group and 532 (98.5%) 
of those who were randomly assigned to the 
placebo group received the assigned treatment, 
a mean of 1.2±1.1 hours after randomization 
(Table S2). The mean baseline 25-hydroxyvitamin 
D level as measured by liquid chromatography–
tandem mass spectrometry was 11.2±4.8 ng per 
milliliter (28±12 nmol per liter) in the vitamin D 
group and 11.0±4.7 ng per milliliter (27±12 nmol 
per liter) in the placebo group (Table 1). In the 
first 25% of patients who had day 3 plasma 
specimens (per-protocol subgroup), the mean 
day 3 level of 25-hydroxyvitamin D as measured by 
liquid chromatography–tandem mass spectrom-
etry was 46.9±23.2 ng per milliliter (117±58 nmol 
per liter) in the vitamin D group and 11.4±5.6 ng 
per milliliter (28±14 nmol per liter) in the pla-
cebo group (difference, 35.5 ng per milliliter; 
95% confidence interval [CI], 31.5 to 39.6) (Ta-
ble 2). In the vitamin D group, most patients 
(74.5%) had reached the target 25-hydroxyvita-
min D level of 30 to less than 120 ng per milli-
liter (75 to <300 nmol per liter) at day 3, with the 
levels in few patients (12.4%) remaining below 
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Characteristic Vitamin D (N = 538) Placebo (N = 540)
Value
No. of Patients 
with Data Value
No. of Patients 
with Data
Demographic
Age — yr 56.5±15.9 538 54.6±16.7 540
Female sex — no. (%) 229 (42.6) 538 238 (44.1) 540
Race or ethnic group — no. (%)†
Non‑Hispanic white 280 (52.0) 538 287 (53.1) 540
Black 130 (24.2) 538 122 (22.6) 540
Nonblack Hispanic 33 (6.1) 538 31 (5.7) 540
Other 15 (2.8) 538 12 (2.2) 540
Not available 80 (14.9) 538 88 (16.3) 540
Facility residence before hospitalization — no. (%) 33 (6.1) 538 35 (6.5) 540
EQ‑5D‑5L score‡ 0.7±0.3 507 0.7±0.3 504
Clinical
Charlson comorbidity index§ 4.0±2.9 522 3.5±2.9 521
Body‑mass index¶ 29.8±10.1 524 31.0±11.4 529
Acute risk factors for death — no. (%)‖
Pneumonia 204 (37.9) 538 181 (33.5) 540
Shock 192 (35.7) 538 197 (36.5) 540
Sepsis 185 (34.4) 538 174 (32.2) 540
Mechanical ventilation for acute respiratory failure 119 (22.1) 538 121 (22.4) 540
Aspiration 27 (5.0) 538 35 (6.5) 540
Lung contusion 15 (2.8) 538 18 (3.3) 540
Pancreatitis 17 (3.2) 538 19 (3.5) 540
Smoke inhalation 1 (0.2) 538 2 (0.4) 540
Medical ICU admission — no. (%) 447 (83.1) 538 462 (85.6) 540
Illness severity
Total SOFA score** 5.6±3.6 538 5.4±3.7 540
LIPS†† 5.3±2.9 538 5.3±3.1 540
Mechanical ventilation — no. (%) 173 (32.2) 538 184 (34.1) 540
ARDS — no. (%) 44 (8.2) 538 44 (8.1) 540
Vasopressor use at baseline — no. (%) 169 (31.4) 538 177 (32.8) 540
Vitamin D–related
Vitamin D supplement use in past week — no. (%) 31 (5.8) 538 24 (4.4) 540
Multivitamin use in past week — no. (%) 38 (7.1) 538 37 (6.9) 540
Estimated average daily vitamin D dose — IU 3269±13,118 57 4252±15,094 54
25‑hydroxyvitamin D level — ng/ml 11.2±4.8 11.0±4.7
Total calcium level — mg/dl 8.3±0.9 528 8.3±0.9 526
Ionized calcium level — mg/dl 4.3±1.4 210 4.3±0.9 212
Creatinine level — mg/dl 2.2±2.3 535 2.0±2.0 539
eGFR — ml/min/1.73 m2 60±39.3 535 60.9±36.9 539
*  Plus–minus values are means ±SD. The primary analysis population included all patients who underwent randomization and had vitamin D 
deficiency confirmed by liquid chromatography–tandem mass spectrometry. Percentages may not total 100 because of rounding. To con‑
vert the values for 25‑hydroxyvitamin D to nanomoles per liter, multiply by 2.496. To convert the values for calcium to millimoles per liter, 
multiply by 0.250. To convert the values for creatinine to micromoles per liter, multiply by 88.4. ARDS denotes acute respiratory distress 
syndrome, and eGFR estimated glomerular filtration rate.
†  Race and ethnic group were reported by the patient or the patient’s surrogate.
‡  Scores on the EuroQol–5 Dimensions 5‑Level quality‑of‑life assessment (EQ‑5D‑5L) range from −0.11 to 1.00, with higher scores indicating 
better health.
§  Charlson comorbidity index scores range from 0 to 37, with higher scores indicating more coexisting conditions.
¶  Body‑mass index is the weight in kilograms divided by the square of the height in meters.
‖  Patients may have had more than one risk factor.
**  The total Sequential Organ Failure Assessment (SOFA) score ranges from 0 to 24, with higher scores indicating more severe organ failure.
††  The Lung Injury Prediction Score (LIPS) ranges from 0 to 36, with higher scores indicating a higher risk of lung injury.
Table 1. Baseline Characteristics of the Patients in the Primary Analysis Population.*
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20 ng per milliliter (Table 2). In the placebo 
group, 94.0% of patients had 25-hydroxyvitamin D 
levels that remained below 20 ng per milliliter at 
day 3. These results were similar in the screened-
deficient population (Tables S1 and S3).
Primary End Point
In the primary analysis population, 90-day all-
cause, all-location mortality was 23.5% in the 
vitamin D group (125 of 531 patients) and 20.6% 
in the placebo group (109 of 528 patients) (dif-
ference, 2.9 percentage points; 95% CI, −2.1 to 
7.9; P = 0.26) (Table 2 and Fig. 2). In the screened-
deficient population, 90-day all-cause, all-location 
mortality was 23.3% in the vitamin D group 
(159 of 681 patients) and 20.9% in the placebo 
group (137 of 656 patients) (difference, 2.5 per-
centage points; 95% CI, −2.0 to 6.9; P = 0.28) 
(Table S3 and Fig. S2). On the basis of the range 
of baseline 25-hydroxyvitamin D levels and pre-
specified thresholds for this measurement, there 
was no apparent interaction between treatment 
group and the baseline 25-hydroxyvitamin D 
level (Fig. 3 and Figs. S2 and S3 and Table S4). 
The observed mortality was higher in the vita-
min D group than in the placebo group for 
several subgroups: patients with sepsis or infec-
tion in the primary analysis population and pre-
hospital facility residence, pneumonia, infection, 
and prerandomization acute respiratory distress 
syndrome in the screened-deficient population.
Secondary End Points
In the primary analysis population, mortality to 
day 28, hospital mortality to day 90, hospital 
and health care facility length of stay, ventilator-
free days, and change in EQ-5D-5L score did not 
differ significantly between the groups (Table 2). 
The postrandomization incidence of acute respi-
ratory distress syndrome did not differ signifi-
cantly between the two treatment groups (4.9% 
in the vitamin D group and 4.1% in the placebo 
group; difference, 0.7 percentage points; 95% 
CI, −2.1 to 3.6). Other physiological end points, 
including respiratory, kidney, and cardiovascular 
failure, were also similar in the two groups. 
Results for secondary end points were similar in 
the screened-deficient population.
Safety and Adverse Events
Safety and adverse events are summarized in 
Table 2 and Tables S5 through S7. Although 
there were 296 total deaths reported in the trial, 
none were adjudicated as being causally related to 
vitamin D or placebo. Prespecified vitamin D–
related adverse events (hypercalcemia, kidney 
stones, and fall-related fractures) were similar in 
the two groups. There was a small increase in 
the highest total calcium level to day 14 in the 
vitamin D group. Similarly, there were small 
increases in total and ionized calcium levels ac-
cording to trial day in the vitamin D group in the 
primary analysis population and the screened-
deficient population. Reported serious and non-
serious adverse events were uncommon and 
similar in the vitamin D and placebo groups 
across the populations.
Discussion
A single 540,000 IU enteral dose of vitamin D3 
administered early during critical illness rapidly 
corrected vitamin D deficiency but did not pro-
vide an advantage over placebo with respect to 
mortality or other clinically important end points. 
The very low likelihood of finding a benefit jus-
tified stopping the trial for futility before the 
pretrial sampling target of up to 3000 patients 
had been reached. We enrolled the intended 
population in a blinded fashion, with 90-day 
mortality similar to the predefined estimated rate, 
and a robust vitamin D response was achieved, 
with few adverse events. No predefined sub-
groups appeared to benefit from the vitamin D 
supplementation, including those with more se-
vere vitamin D deficiency and those with spe-
cific acute risk factors for death. Furthermore, 
the higher observed mortality in the vitamin D 
group among patients with infectious causes of 
illness and patients with prerandomization acute 
respiratory distress syndrome was unexpected 
and contrary to the reported immunomodulatory 
effects of vitamin D. This observation may re-
f lect differences between the use of vitamin D 
for prevention in previous studies24 and the use 
of vitamin D as treatment during acute illness in 
the present trial, but it also may be the result of 
chance.
There are several important differences be-
tween the current phase 3 trial and the previous, 
phase 2 trial (VITdAL-ICU).16,25 First, we enrolled 
patients early in their critical illness, often be-
fore arrival in the ICU, to correct vitamin D de-
ficiency before established critical illness. The 
phase 2 trial enrolled patients a mean of 3 days 
after admission to the ICU. Second, the current 
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trial primarily enrolled typical medical patients 
in the ICU (e.g., patients with pneumonia, sep-
sis, shock, or respiratory failure), whereas more 
than three quarters of the patients in the phase 2 
trial were surgical or neurologic patients in the 
ICU. Third, we did not provide additional vita-
min D supplementation after the initial loading 
dose, on the basis of the expected 2-to-3-week 
half-life of 25-hydroxyvitamin D,11,15,16 which we 
believed was adequate. Fourth, to maximize the 
inclusion of patients who were most likely to 
benefit from vitamin D supplementation, our 
primary analysis was based on liquid chroma-
tography–tandem mass spectrometry testing, the 
criterion standard for 25-hydroxyvitamin D mea-
surement. However, the results were not material-
ly different in the screened-deficient population. 
Fifth, the population in the present trial had 
racial and ethnic diversity representative of the 
U.S. population; the phase 2 trial was conducted 
in Austria, and more than 99% of the patient 
population was white. Given known differences 
in vitamin D metabolism and response genes 
according to race and ethnic group,26-28 such dif-
ferences may affect the results.
The results of the present trial do not support 
early testing for or treatment of vitamin D defi-
ciency in critically ill patients. Ongoing studies 
will evaluate the effect of vitamin D supplemen-
tation in patients with severe vitamin D defi-
ciency (ClinicalTrials.gov number, NCT03188796), 
other subgroups of patients that may be more 
likely to benefit (National Institutes of Health 
project number R01HL144566), and long-term 
outcomes (NCT03733418).
The strengths of our trial included a large, 
diverse, and representative population of patients 
with critical illness who were efficiently enrolled 
early during their critical illness. Our trial also 
achieved strong separation between the groups, 
with rapid correction of vitamin D deficiency. 
The trial also had certain limitations. One was 
the exclusion of patients later in the course of 
critical illness, which may have biased the trial 
population toward patients with less severe ill-
ness because of an inability to obtain timely 
informed consent from patients who had more 
severe illness. We did not follow the outcomes 
among patients who did not undergo random-
ization because they were found not to be vita-
min D–deficient during screening. Finally, we 
did not provide additional vitamin D supplemen-
tation after the loading dose, since our intent 
was early correction of vitamin D deficiency.
In this phase 3 trial, early administration of 
high-dose enteral vitamin D3 did not provide an 
Figure 2. Survival to Day 90 in the Primary Analysis Population.
This figure is descriptive and not intended for inference of effects.
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spectrometry. Estimates were obtained from the quadratic smoothing spline 
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advantage over placebo with respect to 90-day 
mortality or other measures of nonfatal out-
comes among critically ill patients with vitamin 
D deficiency.
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